CA2154161A1 - Therapeutic uses and delivery systems of dehydroepiandrosterone - Google Patents

Therapeutic uses and delivery systems of dehydroepiandrosterone

Info

Publication number
CA2154161A1
CA2154161A1 CA002154161A CA2154161A CA2154161A1 CA 2154161 A1 CA2154161 A1 CA 2154161A1 CA 002154161 A CA002154161 A CA 002154161A CA 2154161 A CA2154161 A CA 2154161A CA 2154161 A1 CA2154161 A1 CA 2154161A1
Authority
CA
Canada
Prior art keywords
precursors
dehydroepiandrosterone
treatment
prevention
sex steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002154161A
Other languages
French (fr)
Other versions
CA2154161C (en
Inventor
Fernand Labrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
Original Assignee
Fernand Labrie
Endorecherche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fernand Labrie, Endorecherche Inc. filed Critical Fernand Labrie
Priority claimed from PCT/CA1994/000022 external-priority patent/WO1994016709A2/en
Publication of CA2154161A1 publication Critical patent/CA2154161A1/en
Application granted granted Critical
Publication of CA2154161C publication Critical patent/CA2154161C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Abstract

Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
CA002154161A 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone Expired - Lifetime CA2154161C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US561993A 1993-01-19 1993-01-19
US08/005,619 1993-01-19
US08/180,361 1994-01-18
US08/180,361 US5776923A (en) 1993-01-19 1994-01-18 Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
PCT/CA1994/000022 WO1994016709A2 (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Publications (2)

Publication Number Publication Date
CA2154161A1 true CA2154161A1 (en) 1994-08-04
CA2154161C CA2154161C (en) 2006-12-12

Family

ID=21716809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002154161A Expired - Lifetime CA2154161C (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Country Status (10)

Country Link
US (6) US5776923A (en)
EP (1) EP1382340B1 (en)
CN (3) CN102357247A (en)
CA (1) CA2154161C (en)
DK (1) DK1382340T3 (en)
IL (5) IL181016A0 (en)
MY (2) MY134585A (en)
SK (1) SK286664B6 (en)
UA (1) UA73911C2 (en)
ZA (1) ZA94372B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021323A1 (en) * 2007-08-10 2009-02-19 Endorecherche, Inc. Dhea compositions for treating menopause
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
AU2012204083B2 (en) * 2007-08-10 2014-10-09 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
TR200100063T2 (en) * 1998-06-11 2001-05-21 Endorecherche, Inc Pharmaceutical compositions and uses for Androst-5-en-3ß, 17ß-diol
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR100302372B1 (en) * 1998-07-24 2001-12-05 박상철 Dihydroepiandrosterone derivatives for the prevention and treatment of osteoporosis
US6726673B1 (en) * 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CN101543500A (en) 1999-03-18 2009-09-30 基因实验室技术公司 Dhea composition and method
WO2000074684A1 (en) * 1999-06-04 2000-12-14 The General Hospital Corporation Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP1955700B9 (en) 1999-09-30 2011-09-07 Harbor BioSciences, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (en) * 1999-10-13 2004-04-30 Oreal USE OF DHEA OR ITS PRECURSORS OR METABOLIC DERIVATIVES AS DEPIGMENTANT
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
FR2803519B1 (en) * 2000-01-12 2002-03-22 Assist Publ Hopitaux De Paris ORAL USE OF DEHYDROEPIANDROSTERONE, ITS PRECURSORS AND DERIVATIVES FOR IMPROVING THE PAPYRACE OF THE SKIN
KR20020073566A (en) * 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 Selective estrogen receptor modulators in combination with estrogens
WO2001062259A1 (en) 2000-02-25 2001-08-30 Hollis Eden Pharmaceuticals Method of treatment of prostate cancer
FR2807323A1 (en) 2000-04-10 2001-10-12 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING A STEROID AND A 2-ALKYL ALKANOL OR AN ESTER
EP1289519B1 (en) 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
AU2001286995B2 (en) * 2000-08-30 2006-11-30 Besins Healthcare Luxembourg Sarl Method for treating erectile dysfunction and increasing libido in men
JP2004507511A (en) * 2000-08-30 2004-03-11 ユニメッド・ファーマシューティカルズ・インコーポレーテッド Methods for increasing testosterone and related steroid levels in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SI1347764T1 (en) * 2000-12-22 2007-06-30 August Wolff Gmbh & Co Kg Arzenmittel Dr Gel composition based on alcohol for the treatment of hypogonadism through transscrotal application
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
ES2312593T3 (en) * 2001-07-09 2009-03-01 Repros Therapeutics Inc. PROCEDURES AND MATERIALS FOR THE TREATMENT OF THE DEFICIENCY OF TESTOSTERONE IN MEN.
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
FR2827764B1 (en) * 2001-07-27 2005-08-19 Oreal COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING A STEROID AND A GLYCOL
FR2828100B1 (en) * 2001-08-02 2004-09-24 Galderma Res & Dev REVERSE EMULSION COMPOSITION CONTAINING DHEA AND / OR ITS PRECURSORS OR DERIVATIVES, AND ITS USE IN COSMETICS AND DERMATOLOGY
EP1350541A1 (en) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Use of dehydroepiandrosterone and an estradiol derivative for preparing a medicament for treating postmenopausal climacteric disorders
WO2003090754A1 (en) * 2002-04-23 2003-11-06 Sahltech I Göteborg AB Use of dhea for treatment of female hypopituitarism
KR100538386B1 (en) * 2002-08-26 2005-12-27 메타볼랩(주) A Pharmaceutical Composition for Treating IL-1 Related Diseases or Disorders
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CA2501874A1 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20050239826A1 (en) * 2004-04-14 2005-10-27 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
CA2595363C (en) * 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
CA3071412A1 (en) * 2005-03-22 2006-09-28 Allergan Pharmaceuticals International Limited Dosing regimes for trans-clomiphene
EP2030622B1 (en) * 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US20080058299A1 (en) * 2005-04-12 2008-03-06 Dudley Robert E Method of treating or preventing bone deterioration or osteoporosis
US8084446B2 (en) 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
JP2009519926A (en) * 2005-12-16 2009-05-21 ライル コーポレート ディベロップメント インコーポレーテッド Regeneration of vaginal tissue by non-systemic vaginal administration of estrogen
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CA2806526C (en) 2007-10-16 2014-12-30 Repros Therapeutics Inc. Trans-clomiphen for type 2 diabetes
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
WO2013098592A1 (en) 2011-12-29 2013-07-04 Universidad De Chile Vaginal ring which includes dhea or dhea sulphate and optionally an agent for modulating the release of the active principle, which can be used to increase the ovarian reserve in women and to relieve symptoms associated with menopause
CN102631677A (en) * 2012-04-19 2012-08-15 中国农业大学 Pharmaceutical composition for preventing and/or treating atherosclerosis
JP2015535283A (en) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド Trans-clomiphene for use in cancer therapy
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth
CN115554403B (en) * 2022-08-16 2024-03-08 山东大学 Use of the steroid hormone DHEA as receptor ADGRG2 agonist ligand

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK122125B (en) * 1967-10-04 1972-01-24 Schering Ag Analogous process for the preparation of therapeutically active carboxylic acid esters of 3β-hydroxy-5-androstan-17-one (dehydroepiandrosterone) having 7-11 carbon atoms in the ester residue.
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
JPS505372A (en) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
DE2534911C2 (en) * 1975-08-01 1985-04-18 Schering AG, 1000 Berlin und 4709 Bergkamen Process for the preparation of 5-androsten-17-one derivatives
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879A1 (en) * 1981-12-30 1983-07-01 Besins Jean Topical oestradiol compsns. - for treatment of disorders associated with menopause
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
SE8303031D0 (en) * 1983-05-30 1983-05-30 Leo Ab IMPROVED STEROID ESTERS PREPARATION
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (en) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (en) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Pharmaceutical preparation suitable for the prophylaxis or therapy of a retroviral infection or a complication or consequence thereof.
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
WO1990006120A1 (en) * 1988-12-01 1990-06-14 Schering Corporation Compositions for transdermal delivery of estradiol
ES2077675T3 (en) * 1989-03-10 1995-12-01 Endorecherche Inc COMBINED THERAPY FOR THE TREATMENT OF ESTROGEN SENSITIVE DISEASES.
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (en) * 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US10076525B2 (en) 2004-10-20 2018-09-18 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women
US10478443B2 (en) 2004-10-20 2019-11-19 Endorecherche, Inc. Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women
WO2009021323A1 (en) * 2007-08-10 2009-02-19 Endorecherche, Inc. Dhea compositions for treating menopause
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2008286651B2 (en) * 2007-08-10 2012-11-22 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8629129B2 (en) 2007-08-10 2014-01-14 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083B2 (en) * 2007-08-10 2014-10-09 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
EA020683B1 (en) * 2007-08-10 2015-01-30 Эндорешерш, Инк. Method for treating or reducing acquiring symptoms or diseases in postmenopausal women, intravaginal composition and suppository used therein
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US8957054B2 (en) 2007-08-10 2015-02-17 Endorecherche, Inc. Pharmaceutical compositions
US10881650B2 (en) 2007-08-10 2021-01-05 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
DK1382340T3 (en) 2006-08-14
SK286664B6 (en) 2009-03-05
ZA94372B (en) 1995-07-19
MY157883A (en) 2016-08-01
MY134585A (en) 2007-12-31
IL181018A (en) 2012-07-31
IL181015A0 (en) 2007-07-04
US5776923A (en) 1998-07-07
IL181018A0 (en) 2007-07-04
EP1382340B1 (en) 2006-04-05
US5780460A (en) 1998-07-14
US5955455A (en) 1999-09-21
CA2154161C (en) 2006-12-12
IL181016A0 (en) 2007-07-04
IL181017A0 (en) 2007-07-04
UA73911C2 (en) 2005-10-17
US5728688A (en) 1998-03-17
US5824671A (en) 1998-10-20
CN101444519A (en) 2009-06-03
IL181015A (en) 2012-12-31
US5922700A (en) 1999-07-13
CN1954804A (en) 2007-05-02
IL181019A0 (en) 2007-07-04
CN102357247A (en) 2012-02-22
EP1382340A1 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
CA2154161A1 (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
WO1994016709A3 (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
US4315925A (en) Method of administering natural female sex hormones
US4383993A (en) Nasal dosage forms containing natural female sex hormones
HU213408B (en) Process for producing pharmaceutical compositions comprising drospirenon
HUP0102483A2 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
CA2391430A1 (en) Improved transdermal contraceptive delivery system and process
Gompel et al. Tibolone actions on normal and breast cancer cells
Ulmann Uses of RU 486 for contragestion: an update
GB2138286A (en) Pharmaceutical composition for the treatment of hair loss
Phillips The selectivity of a new progestin
DE3339295A1 (en) 4-Hydroxy- and 4-acyloxy-4-androstene-3,17-diones for use in the prophylaxis and therapy of prostate hyperplasia and compositions containing these for such a use
IE34308B1 (en) 11beta,13beta dialkylgona-1,3,5(10)-trien-3-ol 3-cycloalkyl ethers
Dorfman et al. The assay of orally administered androgens using the chick's comb
RU1789216C (en) Composition showing contraceptive effect
ITBA920007A1 (en) PHARMACEUTICAL FORMULATIONS FOR THE SYSTEMIC ADMINISTRATION VIA NASAL OF NATURAL FEMALE SEX HORMONES AND AD HORMONES
Dorfman et al. Biosynthesis of steroids in various tissues related to feminizing syndromes
GB1244143A (en) Trialkyl-silyloxy-steroids
KR20010102464A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140120